JP2014527083A5 - - Google Patents

Download PDF

Info

Publication number
JP2014527083A5
JP2014527083A5 JP2014530793A JP2014530793A JP2014527083A5 JP 2014527083 A5 JP2014527083 A5 JP 2014527083A5 JP 2014530793 A JP2014530793 A JP 2014530793A JP 2014530793 A JP2014530793 A JP 2014530793A JP 2014527083 A5 JP2014527083 A5 JP 2014527083A5
Authority
JP
Japan
Prior art keywords
alkoxy
cyano
nitro
alkanoyloxy
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014530793A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014527083A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/055186 external-priority patent/WO2013040227A2/en
Publication of JP2014527083A publication Critical patent/JP2014527083A/ja
Publication of JP2014527083A5 publication Critical patent/JP2014527083A5/ja
Pending legal-status Critical Current

Links

JP2014530793A 2011-09-15 2012-09-13 治療用化合物 Pending JP2014527083A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161535311P 2011-09-15 2011-09-15
US61/535,311 2011-09-15
US201261681519P 2012-08-09 2012-08-09
US61/681,519 2012-08-09
PCT/US2012/055186 WO2013040227A2 (en) 2011-09-15 2012-09-13 Therapeutic compounds

Publications (2)

Publication Number Publication Date
JP2014527083A JP2014527083A (ja) 2014-10-09
JP2014527083A5 true JP2014527083A5 (https=) 2015-08-20

Family

ID=47019147

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014530793A Pending JP2014527083A (ja) 2011-09-15 2012-09-13 治療用化合物

Country Status (6)

Country Link
US (2) US9573906B2 (https=)
EP (2) EP2755942A2 (https=)
JP (1) JP2014527083A (https=)
AU (1) AU2012308582B2 (https=)
CA (1) CA2848540A1 (https=)
WO (1) WO2013040227A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2755942A2 (en) 2011-09-15 2014-07-23 Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University Therapeutic compounds
WO2015026990A2 (en) * 2013-08-20 2015-02-26 University Of Washington Through Its Center For Commercialization Novel and specific inhibitors of cytochrome p450 26 retinoic acid hydrolase
US10328040B2 (en) 2014-01-17 2019-06-25 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic methods
WO2015130973A1 (en) * 2014-02-26 2015-09-03 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
CA2962150C (en) * 2014-10-10 2023-07-04 High Force Research Limited Fluorescent synthetic retinoids
US10112917B2 (en) 2015-03-03 2018-10-30 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
WO2016140978A1 (en) * 2015-03-03 2016-09-09 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US10238655B2 (en) * 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Dihydroindene and tetrahydronaphthalene compounds
US10238626B2 (en) * 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US10231947B2 (en) * 2017-01-23 2019-03-19 Arizona Board Of Regents On Behalf Of Arizona State University Isochroman compounds and methods of use thereof
WO2020263960A1 (en) * 2019-06-28 2020-12-30 Carl Wagner Compositions comprising a retinoid x receptor (rxr) agonist, a retinoic acid receptor (rar) agonist, or a dual rxr/rar agonist

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
DE3441788A1 (de) 1984-11-15 1986-05-15 Bayer Ag, 5090 Leverkusen Alkyl-1-cyclopropyl-1,4-dihydro-4-oxo-3-chinolincarbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US7655699B1 (en) 1992-04-22 2010-02-02 Eisai Inc. Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US5962731A (en) 1992-04-22 1999-10-05 Ligand Pharmaceuticals Incorporated Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US5780676A (en) 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
DE10199033I2 (de) 1992-04-22 2003-01-09 Ligand Parmaceuticals Inc Retinoid-x Rezeptor selektive Verbindungen
US6137002A (en) 1993-07-22 2000-10-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
CA2233888A1 (en) * 1995-10-06 1997-04-10 Ligand Pharmaceuticals Incorporated Dimer-selective rxr modulators and methods for their use
FR2746101B1 (fr) 1996-03-14 1998-04-30 Composes bicycliques-aromatiques
WO1998046076A1 (en) * 1997-04-11 1998-10-22 Sidney Kimmel Cancer Center Retinoid related molecules for the inhibition of endothelin-1 overproduction in disease
FR2776657B1 (fr) * 1998-03-31 2000-05-26 Cird Galderma Composes bicycliques-aromatiques et leur utilisation en medecine humaine ou veterinaire ainsi qu'en cosmetologie
AU762364B2 (en) * 1998-05-06 2003-06-26 Galderma Research & Development, S.N.C. Assay for identification of compounds that promote melanin production and retinoid-like compounds identified by said assay
ATE365158T1 (de) * 1999-04-28 2007-07-15 Inst Med Molecular Design Inc Pyrimidincarbonsäurederivate
US6313107B1 (en) 2000-08-29 2001-11-06 Allergan Sales, Inc. Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
JP2004507531A (ja) 2000-08-29 2004-03-11 アラーガン、インコーポレイテッド シトクロムｐ４５０ｒａｉ阻害剤としての活性を有する化合物
US6303785B1 (en) 2000-08-29 2001-10-16 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6291677B1 (en) 2000-08-29 2001-09-18 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
CN1747949A (zh) 2002-12-20 2006-03-15 法马西亚公司 无环吡唑化合物
AU2004263156B2 (en) * 2003-08-07 2009-02-26 Allergan, Inc. Method for treating cachexia with retinoid ligands
EP1541549A1 (en) 2003-12-12 2005-06-15 Exonhit Therapeutics S.A. Tricyclic hydroxamate and benzaminde derivatives, compositions and methods
US7226951B2 (en) 2003-12-17 2007-06-05 Allergan, Inc. Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
CA2550010A1 (en) 2003-12-17 2005-06-30 Allergan, Inc. Methods for treating retinoid responsive disorders using selective inhibitors of cyp26a and cyp26b
WO2007022437A2 (en) * 2005-08-18 2007-02-22 Auspex Pharmaceuticals, Inc. Therapeutic agents for the treatment of cancer and metabolic disorders
CA2662218A1 (en) * 2006-08-29 2008-03-06 Reinnervate Limited Retinoid compounds and their use
CN113636966B (zh) 2007-01-15 2024-01-12 于崇曦 维生素a酸类和类维生素a酸化合物的前药
WO2010096264A2 (en) 2009-02-03 2010-08-26 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
US20120115912A1 (en) 2009-07-10 2012-05-10 Landreth Gary E Rxr agonist compounds and methods
CN102892755A (zh) * 2009-12-23 2013-01-23 韦恩州立大学 治疗性化合物
US9174917B2 (en) 2010-02-19 2015-11-03 Arizona Board Of Regents On Behalf Of Arizona State University Bexarotene analogs
JP5743129B2 (ja) 2010-04-16 2015-07-01 Dic株式会社 重合性化合物を含有する液晶組成物及びそれを使用した液晶表示素子
EP2755942A2 (en) 2011-09-15 2014-07-23 Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University Therapeutic compounds

Similar Documents

Publication Publication Date Title
JP2014527083A5 (https=)
TWI567067B (zh) ＴｒＫ抑制化合物
WO2014130310A1 (en) Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
JP2015503507A5 (https=)
JP2019517487A5 (https=)
JP2011529049A5 (https=)
RU2662806C2 (ru) 4-алкинилимидазольное производное и лекарственное средство, включающее такое производное в качестве активного ингредиента
JP2016525136A5 (https=)
JP2009523760A5 (https=)
US9233961B2 (en) Compounds and compositions for the treatment of parasitic diseases
JP2014513110A5 (https=)
RU2015151502A (ru) Химические соединения
CN110831926B (zh) 新型四氢萘基脲衍生物
TW201425311A (zh) 新穎之雙環吡啶酮
JP2017505293A5 (https=)
JP2007507494A5 (https=)
JP2019520344A5 (https=)
RU2011121300A (ru) Производные 1,3,4-оксадиазола и их применение для лечения диабета
JP2016525104A5 (https=)
JP2020505354A5 (https=)
JP2011509302A5 (https=)
JP2005522439A5 (https=)
JP2012518634A5 (https=)
JP2020515645A5 (https=)
JP2015502371A5 (https=)